Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risk versus benefit considerations for the beta(2)-agonists.

H William Kelly1

  • 1Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico 87131, USA. hwkelly@unm.edu

Pharmacotherapy
|September 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticholinergics in Chronic Asthma: A Promising Future?

Pediatric allergy, immunology, and pulmonology·2022
Same author

Identification of a key gene module associated with glucocorticoid- induced derangement in bone mineral density in patients with asthma.

Scientific reports·2019
Same author

Challenges in assessing the efficacy of systemic corticosteroids for severe wheezing episodes in preschool children.

The Journal of allergy and clinical immunology·2019
Same author

Combined Analysis of Asthma Safety Trials of Long-Acting β<sub>2</sub>-Agonists.

The New England journal of medicine·2018
Same author

Could calcium channel blockers treat 2 illnesses with 1 pill?

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2017
Same author

Tiotropium Bromide in Children and Adolescents with Asthma.

Paediatric drugs·2017

Short-acting beta(2)-agonists treat acute bronchospasm, while long-acting beta(2)-agonists maintain control in asthma and COPD. This review compares their pharmacology, efficacy, and safety, including stereoisomer effects.

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Therapeutics

Background:

  • Short-acting beta(2)-agonists (SABAs) are primary treatments for acute bronchospasm in asthma and COPD.
  • Long-acting beta(2)-agonists (LABAs) are crucial for maintaining disease control in these respiratory conditions.

Purpose of the Study:

  • To compare the pharmacology of beta(2)-agonists, detailing how differences impact efficacy and adverse effects.
  • To address clinical questions regarding the safety and efficacy of SABAs and LABAs, including cardiovascular effects and tolerance.
  • To review the preclinical and clinical data on racemic albuterol versus levalbuterol (R-albuterol), focusing on stereoisomer effects.

Main Methods:

  • Review of pharmacological properties of beta(2)-agonists.
  • Analysis of clinical data on efficacy and safety of SABAs and LABAs.

Related Experiment Videos

  • Examination of preclinical and clinical studies on albuterol stereoisomers.

    • Main Results:

    • Differences in beta(2)-agonist pharmacology influence their clinical efficacy and side effect profiles.
    • Concerns exist regarding cardiovascular effects, tolerance, and potential masking of asthma control with LABAs.
    • S-albuterol may have proinflammatory effects and increase bronchial hyperreactivity, unlike R-albuterol (levalbuterol).

    Conclusions:

    • Understanding beta(2)-agonist pharmacology is key to optimizing treatment for asthma and COPD.
    • Levalbuterol (R-albuterol) may offer a different safety and efficacy profile compared to racemic albuterol.
    • Pharmacogenetics might influence individual patient response to beta(2)-agonists.